REPL
NASDAQ HealthcareReplimune Group, Inc. - Common Stock
Biotechnology
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
๐ Market Data
| Price | $9.52 |
|---|---|
| Volume | 3,562,325 |
| Market Cap | 799.16M |
| Beta | 0.870 |
| RSI (14-Day) | 28.3 Oversold |
| 200-Day MA | $7.58 |
| 50-Day MA | $8.22 |
| 52-Week High | $13.24 |
| 52-Week Low | $1.50 |
| Forward P/E | -8.25 |
| Price / Book | 4.74 |
๐ฏ Investment Strategy Scores
REPL scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (74/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Over-Hyped (6/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find REPL in your text
Paste any article, transcript, or post โ the tool will extract REPL and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.